Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 29384C108 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
MPM BioVentures 2014, L.P.
13D/A
Amendment 1
|
9.9% |
9/10/2026
Event 9/8/2026
|
|
| MPM BioVentures 2014, L.P. | 4.5% | ||
| MPM BioVentures 2014 (B), L.P. | 0.3% | ||
| MPM Asset Management Investors BV2014 LLC | 0.2% | ||
| MPM BioVentures 2014 GP LLC | 4.8% | ||
| MPM BioVentures 2014 LLC | 5.0% | ||
| MPM Bioventures 2018, L.P. | 4.7% | ||
| MPM Bioventures 2018 (B), L.P. | 0.2% | ||
| MPM Asset Management Investors BV2018 LLC | 0.1% | ||
| MPM BioVentures 2018 GP LLC | 4.9% | ||
| MPM BioVentures 2018 LLC | 5.0% | ||
| Ansbert Gadicke | 9.9% | ||
| Luke Evnin | 9.9% | ||
| Todd Foley | 9.9% | ||
|
TCG Crossover GP I, LLC
13G/A
Amendment 1
|
2.7% |
8/14/2026
Event 6/30/2026
|
|
| TCG Crossover GP I, LLC | 2.7% | ||
| TCG Crossover Fund I, L.P. | 2.7% | ||
| Chen Yu | 2.7% | ||
|
TCG Crossover GP I, LLC
13G
|
5.0% |
11/25/2025
Event 11/19/2025
|
|
| TCG Crossover GP I, LLC | 5.0% | ||
| TCG Crossover Fund I, L.P. | 5.0% | ||
| Chen Yu | 5.0% | ||
|
5AM Ventures V, L.P.
13D/A
Amendment 1
|
10.8% |
11/18/2025
Event 11/14/2025
|
|
| 5AM Ventures V, L.P. | 7.8% | ||
| 5AM Partners V, LLC | 7.8% | ||
| 5AM Opportunities I, L.P. | 2.9% | ||
| 5AM Opportunities I (GP), LLC | 2.9% | ||
| Andrew J. Schwab | 10.6% | ||
| Kush Parmar | 10.8% | ||
| Scott M. Rocklage | 7.8% | ||
| Price T Rowe Associates Inc /MD/ 13G/A Amendment 5 | 0.9% |
11/14/2025
Event 9/30/2025
|
|
| Janus Henderson Group PLC 13G/A Amendment 2 | 4.0% |
8/14/2025
Event 6/30/2025
|
|
| Price T Rowe Associates Inc /MD/ 13G/A Amendment 4 | 6.8% |
8/14/2025
Event 6/30/2025
|
|
|
Janus Henderson Group PLC
13G/A
Amendment 1
|
5.6% |
5/14/2025
Event 3/31/2025
|
|
| Janus Henderson Group PLC | 5.6% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 5.0% | ||
|
Janus Henderson Group PLC
13G
|
5.6% |
2/14/2025
Event 12/31/2024
|
|
| Janus Henderson Group PLC | 5.6% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 5.0% | ||
|
Roche Finance Ltd
13G/A
Amendment 2
|
6.9% |
2/14/2025
Event 12/31/2024
|
|
| Roche Finance Ltd | 6.9% | ||
| Roche Holding Ltd | 6.9% | ||
| BlackRock, Inc. 13G | 5.3% |
2/4/2025
Event 12/31/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 5 | 5.05 k | $32.1 k |
| 2026 Q2 | 131 | 29.4 M | $217 M |
| 2026 Q1 | 121 | 25.5 M | $321 M |
| 2025 Q4 | 117 | 24.4 M | $251 M |
| 2025 Q3 | 120 | 28.6 M | $169 M |
| 2025 Q2 | 111 | 29.6 M | $199 M |
| 2025 Q1 | 114 | 30.2 M | $275 M |
| 2024 Q4 | 109 | 30.7 M | $530 M |
| 2024 Q3 | 103 | 30.1 M | $481 M |
| 2024 Q2 | 89 | 29.8 M | $424 M |
| 2024 Q1 | 81 | 26.3 M | $372 M |
| 2023 Q4 | 66 | 26.4 M | $398 M |
| 2023 Q3 | 57 | 26.0 M | $411 M |
| 2023 Q2 | 57 | 25.8 M | $390 M |
| 2023 Q1 | 54 | 24.9 M | $361 M |
| 2022 Q4 | 49 | 24.8 M | $335 M |
| 2022 Q3 | 34 | 24.5 M | $386 M |
| 2022 Q2 | 39 | 24.8 M | $302 M |
| 2022 Q1 | 50 | 25.9 M | $243 M |
| 2021 Q4 | 47 | 25.4 M | $434 M |